Jean-Jacques Kiladjian, Francisco Cervantes, Franck W G Leebeek, Christophe Marzac, Bruno Cassinat, Sylvie Chevret, Dominique Cazals-Hatem, Aurélie Plessier, Juan-Carlos Garcia-Pagan, Sarwa Darwish Murad, Sebastian Raffa, Harry L A Janssen, Claude Gardin, Sophie Cereja, Carole Tonetti, Stéphane Giraudier, Bertrand Condat, Nicole Casadevall, Pierre Fenaux, Dominique C Valla
Myeloproliferative diseases (MPDs) represent the commonest cause of splanchnic vein thrombosis (SVT), including Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT), but their diagnosis is hampered by changes secondary to portal hypertension, while their influence in the outcome of SVT remains unclear. We assessed the diagnostic and prognostic value of JAK2 and MPL515 mutations in 241 SVT patients (104 BCS, 137 PVT). JAK2V617F was found in 45% of BCS and 34% of PVT, while JAK2 exon 12 and MPL515 mutations were not detected...
May 15, 2008: Blood